This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Jun;57(6):1116-7.

doi: 10.1016/j.eururo.2010.03.024.

Words of wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance

Yair Lotan¹

Affiliations

PMID: 20965050
DOI: 10.1016/j.eururo.2010.03.024

Comment

Words of wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance

Yair Lotan. Eur Urol. 2010 Jun.

. 2010 Jun;57(6):1116-7.

doi: 10.1016/j.eururo.2010.03.024.

Author

Yair Lotan¹

Affiliation

¹ The University of Texas Southwestern Medical Center, Department of Urology, J8.112, Dallas, TX 75390, USA. yair.lotan@utsouthwestern.edu

PMID: 20965050
DOI: 10.1016/j.eururo.2010.03.024

No abstract available

PubMed Disclaimer

Comment on

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S. Addeo R, et al. J Clin Oncol. 2010 Feb 1;28(4):543-8. doi: 10.1200/JCO.2008.20.8199. Epub 2009 Oct 19. J Clin Oncol. 2010. PMID: 19841330 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science